ORIGINAL RESEARCH article
Front. Urol.
Sec. Male Urology
Volume 5 - 2025 | doi: 10.3389/fruro.2025.1565240
This article is part of the Research TopicInnovations and Advancements in the Management of Male Lower Urinary Tract Symptoms (LUTS)View all articles
Comparison of Serenoa Repens, Lycopene and Selenium Versus Dutasteride for theTreatment of LUTS/BPH. An Italian Multicenter Case-Control Prospective Study.(COMP Study)
Provisionally accepted
Giuseppe Morgia1,2*
Arturo Lo Giudice3
Sebastiano Cimino1Giulio Reale4Gaetano Larganà4Enza La Manna4Massimo Madonia5Alessandro Tedde5Francesco Santaniello6Giuseppe Vespasiani7Stefano Zaganelli8Salvatore Arnone8Nicola Cruciano9Maurizio Carrino10Francesco Persico10
Carlo Terrone11Rita Malinaric11
Andrea Minervini12
Marco Carini12
Giorgio Ivan Russo1- 1University of Catania, Catania, Italy
- 2Mediterranean Institute of Oncology (IOM), Viagrande, Italy
- 3University of Messina, Messina, Sicilia, Italy
- 4Urology ravenna, Ravenna, Italy
- 5University of Sassari, Sassari, Sardegna, Italy
- 6Urology Unit Ancona, Ancona, Italy
- 7Urology Unit, Roma, Roma, Italy
- 8Urology Unit Lugo, Lugo di Romagna, Italy
- 9Urology Unit Maria Vittoria Hospital, Torino, Italy
- 10Urology Unit Cardarelli, Naples, Italy
- 11University of Genoa, Genoa, Liguria, Italy
- 12University of Florence, Florence, Tuscany, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction. Historically, medical therapy of BPH has had its foundations in alpha-blockers in monotherapy or in combination with 5 alpha reductase inhibitors (5-ARIs); in particular, two important trials (COMBAT and MTOPS) have demonstrated the pivotal role of combination therapy instead of monotherapy and have individuated which patients are most likely to benefit from alpha-blockers, 5-ARIs, or their combination. However different side effects of these drugs, such erectile dysfunction, ejaculatory disorders, loss of libido, could affect the adherence to treatment. In fact, SeR-Se-Ly would work by blocking 5-alpha reductase and the binding between the dihydrotestosterone and the androgen receptor, antagonizing the a1-adrenergic receptor, and preventing cell proliferation and the production of COX-2 and 5-leukotrienes. Prior randomized controlled trials confirmed the use of alphablockers in conjunction with Lipidic Extract (LE) of Serenoa Repens (SeR), specifically compounds containing both Selenium (Se) and Lycopene (Ly). Based on these premises, the aim of this Italian multicenter case-control prospective non-randomized study is to compare the therapy with SeR-Se-Ly alone versus Dutasteride alone against BPH, in order
Keywords: BPH, Serenoa repens, luts, Prostate, 5ARI
Received: 22 Jan 2025; Accepted: 31 Mar 2025.
Copyright: © 2025 Morgia, Lo Giudice, Cimino, Reale, Larganà, La Manna, Madonia, Tedde, Santaniello, Vespasiani, Zaganelli, Arnone, Cruciano, Carrino, Persico, Terrone, Malinaric, Minervini, Carini and Russo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Giuseppe Morgia, University of Catania, Catania, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.